Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Mefenamic Acid”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 19 recordsLinked to original sources
PubMed1992

A comparison of tiaprofenic acid, mefenamic acid and placebo in the treatment of dysmenorrhoea in general practice.

The efficiency and side-effects of tiaprofenic acid, mefenamic acid and placebo were compared in the treatment of primary dysmenorrhoea. The trial was a double-blind prospective randomized 3-way crossover study during 6 successive menstrual cycles following a 2-cycle run-in period and involved 50 women with primary dysmenorrhoea selected from 96 volunteers between 16 and 35 years of age. Overall pain was significantly less (p less than 0.05) on treatment with tiaprofenic acid than on treatment with mefanemic acid, placebo, or the women's usual treatments. Both active treatments were well tolerated but more side-effects were reported during treatment with mefenamic acid.

Adolescent↗
PubMed1978

Oral antipyretic therapy: evaluation of the N-aryl-anthranilic acid derivatives mefenamic acid, tolfenamic acid and flufenamic acid.

The antipyretic activity of three N-aryl-anthranilic acid derivatives, mefenamic acid, tolfenamic acid and flufenamic acid, was compared and their optimal antipyretic dose determined in a trial in 87 children (aged 5 months to 15 years), who suffered from infections and fever exceeding 38.5 degrees C. Tolfenamic acid proved to be the most potent antipyretic agent of the three drugs; it was eight times more powerful than mefenamic acid and three times more powerful than flufenamic acid. The optimal antipyretic doses were: mefenamic acid 4 mg/kg, tolfenamic acid 0.5 mg/kg and flufenamic acid 1.5 mg/kg. It is evident that the antipyretic activity of these anthranilic acid derivatives is even greater than their antirheumatic effect, the difference being most noticeable in the case of tolfenamic acid.

Adolescent↗
PubMed1977

Oral antipyretic therapy. Evaluation of mefenamic acid (short communication).

The capacity of N-(2,3-xylyl)anthranilic acid (mefenamic acid) to reduce fever in children was compared with that of acetylsalicylic acid, paracetamol and amino-phenazone. The series of cases consisted of 71 patients in the age range from 3 months to 15 years and with rectal temperatures above 38.5 degrees C. Temperatures were recorded at 15 and 30 min, and 1, 2, 4 and 6 h after challenge with the drug. The antipyretic effect of mefenamic acid in a dose of 4 mg/kg was optimal: it was 2.5 times that of acetyl-salicylic acid or paracetamol and nearly similar to that of aminophenazone. It seems possible that the antipyretic effect of mefenamic acid is stronger than its anti-inflammatory and analgetic properties.

Acetaminophen↗
PubMed1992

Rapid and sensitive liquid chromatographic assay of mefenamic acid in plasma.

Mefenamic acid (MA) is a nonsteroidal antiinflammatory analgesic agent widely used clinically. A simple and sensitive liquid-chromatographic assay has been developed for the quantitative determination of MA in human plasma. A reverse phase, 10-microns cyano column (25 x 0.4 cm), a mobile phase of water-acetonitrile-methanol-17 M acetic acid (69:15:15:1 by volume), and an ultraviolet detection (290 nm) are used for the separation of MA and internal standard (methyl-clonazepam). MA and internal standard are extracted from acidified plasma into diethyl ether and after evaporation of the organic phase, the residue is redissolved in methanol. Calibration curves are linear in the range 0.05-3.20 micrograms/ml, and at the plasma level corresponding to the quantification limit (0.05 microgram/ml) coefficients of variation are 7.5% and 10.2% for repeatability and reproducibility studies, respectively. This assay was successfully used in the study of pharmacokinetics of MA in human plasma after a single oral administration of a low MA dose.

Carbamazepine↗
PubMed1992

Fixed drug eruption to mefenamic acid: a report of three cases.

Mefenamic acid (Ponstan) is widely used in the treatment of dysmenorrhoea, menorrhagia, and musculoskeletal pain. Although only 17 cases of fixed drug eruption provoked by mefenamic acid have been reported in the world literature, in a 7-day period a further three patients with fixed drug eruption due to mefenamic acid presented to the dermatology out-patient clinic of the University Hospital of Wales, Cardiff. The lesions of all the patients became inflamed within a few hours of taking the drug, but two of the three patients failed to appreciate the association. There have been no further episodes of inflammation since the patients avoided mefenamic acid.

Adult↗
PubMed1979

Electroencephalographic affects of an anti-inflammatory analgesic: mefenamic acid.

A study of the electroencephalographic patterns observed following iv administration of increasing doses of mefenamic acid in acute experiments on curarized cats and rats and the possible modification of these effects by naloxone was carried out. Mefenamic acid produced in both species a progressive and dose-related increase of the voltage of the baseline patterns. With high doses, besides slow waves and fusiform complexes, an irritative activity with spikes and complexes of polyspikes was observed. The recovery of the basal activity was obtained within 15 min, except for the highest dose, under which the effect lasted 30 min after administration. Cats displayed a higher sensitivity than did rats. Naloxone did not modify the EEG effects of mefenamic acid, neigher in rats nor in rats. This fact suggests that the locus of action of these drugs is different. Mefenamic acid appears to act centrally with relatively short-lasting depressant effects at low doses and facilitating or stimulant effects at high doses.

Animals↗
PubMed1976

Gastritis, duodenitis, and bleeding duodenal ulcer following mefenamic acid therapy.

A 46-year-old woman developed hematemesis and melena two weeks after starting mefenamic acid therapy for osteoarthritis of the spine. Esophagogastroduodenoscopy, arteriography, and a laparotomy revealed antral gastritis, duodenitis, and an acute bleeding ulcer in the third portion of the duodenum. Although mefenamic acid has many of the pharmacologic and physicochemical properties of aspirin and produces gastrointestinal ulceration in animals when administered in large doses, the English literature reveals only one case of gastric ulceration and a single instance of upper-gastrointestinal tract hemorrhage associated with its use. This case warns that mefenamic acid may cause serious gastric and duodenal inflammation and ulceration more commonly than is presently suspected.

Duodenal Diseases↗
PubMed1977

Mefenamic acid compared with ibuprofen in the treatment of rheumatoid arthritis.

A randomized double-blind within-patient study of mefenamic acid compared with ibuprofen was performed on forty patients with rheumatoid arthritis. It was concluded that mefenamic acid and ibuprofen had an analgesic and anti-inflammatory effect which was not significantly different in the dosages employed. Apart from six complaints of drowsiness of ibuprofen with two complaints on mefenamic acid, the side-effects were similar.

Arthritis, Rheumatoid↗
PubMed1992

Effects of mefenamic acid on menstrual hemostasis in essential menorrhagia.

Prostaglandin synthesis inhibitors decrease menstrual blood loss by 30% to 50% in patients with essential menorrhagia. To obtain insight into their mechanism of action, we measured menstrual blood loss in menorrhagic women, who were receiving mefenamic acid (500 mg, three times daily) (n = 6) or placebo (n = 5) in a double-blind way. In addition we studied the morphology of early menstrual hemostasis. The subjects' uteri were extirpated in the first 24 hours of menstruation, and light and electron microscopy were used to perform morphologic and morphometric studies. In the group treated with mefenamic acid mean menstrual blood loss was decreased by 40%. In uteri of the women treated with mefenamic acid hemostatic plugs were further transformed, and fewer vessels without a plug were observed than in uteri of the group receiving placebo. These data suggest that mefenamic acid may act through an improvement of platelet aggregation and degranulation and through increased vasoconstriction.

Adult↗
PubMed1978

[Autoimmune hemolytic anemia induced by mefenamic acid].

A case of autoimmunohemolytic anemia following mefenamic acid therapy is described. A free anti-erythrocytic antibody of the IgG class was found in the serum of the patient. The same antibody was also found in the eluate of the patient's red cells. No blood group specificity could be demonstrated. Direct participation of the drug in the antibody red cell reaction could be ruled out by "facilitation" and "inhibition" tests.

Anemia, Hemolytic, Autoimmune↗
PubMed1976

Comparison of effectiveness of mefenamic acid and ibuprofen in treatment of rheumatoid arthritis.

This paper reports a double-blind crossover trial comparing mefenamic acid (1500 mg/day) with ibuprofen (1200 mg/day) in the treatment of patients with rheumatoid arthritis receiving maintenance salicylate therapy. Both drugs were used in three divided doses. Mefenamic acid compared favourably with ibuprofen. In the adopted dose regimes the side effects from both drugs were mild and almost exclusively gastrointestinal.

Arthritis, Rheumatoid↗
PubMed1992

Mefenamic acid in prevention of premature labour.

Women at risk of premature delivery were divided randomly into 2 groups of 80 each. Mefenamic acid 500mg 3 times a day or a placebo was given in a double blind fashion. Preterm delivery occurred in 15% of the treated group and 40% of the control group (p < 0.005). The mean birth weight in the test group was higher as compared to the controls. There were no cases of foetal malformations in either of the groups. The results support the use of Mefenamic acid in preventing premature labour.

Adolescent↗
PubMed1979

A double-blind, crossover trial of mefenamic acid, sulindac and flurbiprofen in rheumatoid arthritis.

A double-blind crossover trial was carried out in 24 patients to compare the effects of mefenamic acid, flurbiprofen, sulindac and placebo. Each drug was given for 2 weeks, the treatment sequence being randomized. Daily doses were 1500 mg mefenamic acid, 150 mg flurbiprofen or 150 mg sulindac. All of the active drugs were significantly superior to placebo in terms of pain score, patients' assessment, articular index of joint tenderness, and duration and severity of morning stiffness. There was improvement in grip strength compared with placebo, but the differences were not statistically significant with sulindac. There was slight reduction in joint circumference but this was only statistically significant in the right hand with flurbiprofen and sulindac. No significant differences were found in technetium uptake in knee joints. The three drugs appeared to be equally effective and tolerated, and no significant differences were noted.

Adult↗
PubMed1977

Mefenamic acid: an under-rated antirheumatic?

A double-blind crossover study was carried out in 18 patients with classical rheumatoid arthritis to assess the effectiveness of mefenamic acid (500 mg t.d.s.) compared with placebo or indomethacin (25 mg q.d.s.). Each treatment was given for 1 week and subjective and objective assessments were carried out at the end of each period. Results showed that both mefenamic acid and indomethacin were significantly better than placebo in most parameters. Although duration of morning stiffness and patient preference favoured indomethacin it was considered that there was no demonstrable difference of any clinical significance between the two active medications.

Adult↗
PubMed1977

Mefenamic acid and dextropropoxyphene with paracetamol as analgesics in the accident department.

A double-blind study was carried out in 48 patients with soft-tissue injuries to compare the effectiveness of mefenamic acid and dextropropoxyphene plus paracetamol in relieving acute post-injury pain. Patients received capsules containing either 250 mg mefenamic acid or 32.5 mg dextropropoxyphene hydochloride plus 325 mg paracetamol and were instructed to take up to 6 capsules daily as necessary. By the third post-injury day both preparations had controlled pain adequately and lessened local tenderness in most cases. There was no significant difference in response between the two patient groups. Two patients in each group stopped treatment because of gastro-intestinal intolerance, and a further 4 patients in each group reported troublesome side-effects.

Acetaminophen↗
PubMed1992

Case report: acute renal failure, thrombocytopenia and nonhemolytic icterus probably caused by mefenamic acid (Parkemed)-dependent antibodies.

A 65-year-old, previously healthy man developed acute renal failure, severe thrombocytopenia and hepatic icterus after a small dose of mefenamic acid (Parkemed). Drug-dependent antibodies reacting against platelets could be identified as the most probable cause for this acute and rapidly reversible disorder. A concomitant hemolytic reaction was not observed and accordingly no drug-dependent red cell antibodies could be demonstrated. The drug-specific antibodies were found only during the acute phase using the platelet immunofluorescence test and a solid-phase immunoassay but not with the monoclonal antibody specific immobilization of platelet antigens assay. After discontinuation of the drug the patient steadily improved and fully recovered until day 22 after admission and drug removal. The clinical course strongly suggests that drug-dependent antibodies against mefenamic acid and/or its metabolites reacting by immune complex mechanism were responsible not only for the thrombocytopenia but also for the renal and hepatic failure.

Acute Kidney Injury↗
PubMed1975

Studies on Ponstan (mefenamic acid): I. Gastro-intestinal blood loss; II. Absorbtion and excretion of a new formulation.

Using improved techniques in a study of faecal blood loss no significant change over control level occurred during administration of mefenamic acid 500 mg t.i.d. for six days. This lack of gastro-intestinal bleeding is at variance with earlier findings for this compound. Studies of two mefenamic acid formulations (250 mg capsule and 500 mg filmseal tablet) showed no significant difference in area under blood level curves or in urinary output data, indicating equivalent total absorption. The 500 mg film-coated tablet gave significantly higher serum levels at 0.5 hours, whereas the 250 mg capsule gave significantly higher serum levels at 6 and 8 hours.

Adult↗